Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which engages in the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 168 full-time employees. The company went IPO on 2020-05-22. The firm's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers dermatology (such as hair loss, acne) and tumor indications. The firm has two core drugs in the dermatology field, KX-826 and GT20029. The firm's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.
Follow-Up Questions
Who is the CEO of Kintor Pharmaceutical Ltd?
Dr. Tong Youzhi is the Executive Chairman of the Board of Kintor Pharmaceutical Ltd, joining the firm since 2018.
What is the price performance of KNTPF stock?
The current price of KNTPF is $0.2588, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Kintor Pharmaceutical Ltd?
Kintor Pharmaceutical Ltd belongs to Biotechnology industry and the sector is Health Care
What is Kintor Pharmaceutical Ltd market cap?
Kintor Pharmaceutical Ltd's current market cap is $121.1M
Is Kintor Pharmaceutical Ltd a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Kintor Pharmaceutical Ltd, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
